ArticleScientific reports2026
Enhanced cytotoxic activity and pH-responsive drug delivery of quinalizarin-conjugated gold nanoparticles in non-small cell lung cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Casein kinase 2 (CK2) is a key regulator of cancer cell survival and proliferation, making it an attractive therapeutic target. Quinalizarin is a potent CK2 inhibitor; however, its clinical application is limited by suboptimal delivery and bioavailability. This study aimed to develop and characterize a quinalizarin-gold nanoparticle nanocomplex (QGNPs) and evaluate its potential to enhance anticancer activity in non-small cell lung cancer (NSCLC). QGNPs were synthesized using sulfhydryl calcium acetate as a linking agent. The nanocomplex was characterized by UV-Vis spectroscopy, dynamic light scattering, zeta potential analysis, and transmission electron microscopy. Drug loading and release profiles were assessed using UV-Vis spectroscopy. In vitro cytotoxicity was evaluated in A549 lung cancer cells using MTT assay, and cellular uptake was examined by confocal laser scanning microscopy. QGNPs demonstrated successful conjugation, with an increase in particle size from ~ 15 to 85.18 ± 8.25 nm and a zeta potential shift to - 19.59 ± 5.62 mV. The nanocomplex exhibited pH-responsive drug release, with significantly higher quinalizarin release under acidic conditions (pH 5.0) compared to physiological pH (7.4). In vitro studies showed that QGNPs significantly enhanced cytotoxic activity compared to free quinalizarin, with lower IC₅₀ values. Confocal microscopy confirmed efficient intracellular uptake of QGNPs in A549 cells. QGNPs represent a promising nanocarrier system for improving the delivery and anticancer efficacy of quinalizarin in NSCLC. The enhanced cytotoxicity and pH-responsive release suggest potential for targeted cancer therapy. However, further studies are required to elucidate underlying mechanisms and to evaluate radiosensitization and in vivo therapeutic efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.